EMA suggests halt on Servier's Protelos; Harvard sacked ex-SAC manager for fraud; FDA approves Merck HIV drug for infants;

@FiercePharma: Best-read FiercePharma special yesterday: Top 10 Drug Patent Losses of 2014. Report | Follow @FiercePharma

@TracyStaton: Top FiercePharma news Thursday: Wanna trade? Novartis + Merck reportedly negotiating $5B unit swap. Story | Follow @TracyStaton

@EricPFierce: Genentech liquid Tamiflu delays stem from packaging issues. Shortages possible but capsules available. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: With CEO pick, Teva bets turnaround savvy will trump pharma know-how. Thursday's story | Follow @CarlyHFierce

> The EMA has recommended suspending sales of bone-building drug Protelos made by French drugmaker Servier because of blood clot and heart risks. Story

> Some doctors in the U.K. are suggesting that new drug payment guidelines will favor the young over the old and sick. More

> The FDA has approved a new formulation of Merck ($MRK) Isentress to treat infants and children with HIV infection. Report

> Dr. Reddy's Laboratories is launching anti-hypertension drug, Optidoz, in India. Report

> A group of U.S. Blue Cross insurers are creating the world's biggest provider network for international health-insurance customers. Story

Medical Device News

@FierceMedDev: St. Louis spinal/sports medicine co. ISTO Technologies names George Dunbar CEO. Release | Follow @FierceMedDev

@MichaelGFierce: Global nanomed market, driven by brain delivery, is expected to reach $177B by 2019. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: How much is that artificial hip? Your doctor probably doesn't know. Story | Follow @EmilyWFierce

@MarkHFierce: Three heavy-hitters--Covidien, NEA and Lightstone--are jointly investing in a new Irish med tech company. Release | Follow @MarkHFierce

> PureTech's Tal Medical faces a clinical test of its rapid depression treatment. Editor's corner

> Endo finally ditches its urology tech business for up to $130M. More

> Inspire Medical's sleep apnea implant scores for majority in study. Story

Biotech News

@FierceBiotech: MannKind has an FDA advisory committee review of Afrezza set for April 1. Release | Follow @FierceBiotech

@JohnCFierce: 1 of today's top stories: Ex-$BMS R&D chief Sigal makes the leap into venture finance. Joins Mott at NEA. Story | Follow @JohnCFierce

@DamianFierce: Analyst says Lombard's U.S. IPO could come in at $70M. EP Vantage story | Follow @DamianFierce

@EmilyMFierce: Blast at San Francisco Amgen lab injures 2. Story | Follow @EmilyMFierce

> FDA reviewer flunks Chelsea's effort at a comeback for Northera. Story

> It's an industry tradition: Biopharma gets giddy as JPMorgan gets the party started. Article

> Amgen spinoff Atara cranks its Series B up to $52M. Report

And Finally... Ahead of the trial of a former SAC hedge fund manager for insider trading in pharma stocks, unsealed documents show he was kicked out of Harvard Law School for faking his grades. Story

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.